Form 4: SLNO Director Hahn Granted 10,046 Restricted Stock Units

Soleno Therapeutics Director Mark W. Hahn was granted 10,046 restricted stock units, vesting over three years, aligning his interests with shareholders.

Summary

• Mark W. Hahn, a Director of SOLENO THERAPEUTICS INC (SLNO), acquired 10,046 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was October 13, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock.
• The RSUs will vest in three equal annual installments, with one-third vesting on October 13, 2026, and one-third on each subsequent one-year anniversary.
• Vesting is contingent upon Mr. Hahn continuing to be a Service Provider through each vesting date.
• Following this transaction, Mr. Hahn beneficially owns 10,046 shares of Common Stock (in the form of RSUs).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The grant of Restricted Stock Units to a director aligns management's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The future outlook for the granted RSUs is tied to the director's continued service and the company's stock performance, with vesting scheduled annually over the next three years.

Industry Context

The grant of restricted stock units is a common form of equity compensation for directors in publicly traded companies, used to attract, retain, and incentivize leadership by aligning their financial interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• One-third of the granted RSUs are scheduled to vest on October 13, 2026, subject to the director's continued service.
• Subsequent one-third portions of the RSUs will vest on each one-year anniversary thereafter, contingent on continued service.

Key Dates

Keywords

SOLENO THERAPEUTICS, SLNO, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Stock Grant, Equity Compensation